Literature DB >> 16336004

Oncogenes as novel targets for cancer therapy (part IV): regulators of the cell cycle and apoptosis.

Zhuo Zhang1, Mao Li, Elizabeth R Rayburn, Donald L Hill, Ruiwen Zhang, Hui Wang.   

Abstract

This is the final part of a four-part serial review on oncogenes and their potential use as targets for cancer therapy. Previous sections discussed various categories of oncogenes (growth factors, tyrosine kinases, intermediate signaling molecules, and transcription factors) and the advances made in various strategies being used to alter their actions. This part describes four oncogenes, MDM2, BCL2, XIAP, and Survivin, that are involved in regulation of the cell cycle and apoptosis.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16336004     DOI: 10.2165/00129785-200505060-00006

Source DB:  PubMed          Journal:  Am J Pharmacogenomics        ISSN: 1175-2203


  3 in total

1.  Use of recombinant cell-permeable small peptides to modulate glucocorticoid sensitivity of acute lymphoblastic leukemia cells.

Authors:  Chuan-dong Geng; Wayne V Vedeckis
Journal:  Biochemistry       Date:  2010-10-19       Impact factor: 3.162

2.  Kaempferol induced the apoptosis via cell cycle arrest in human breast cancer MDA-MB-453 cells.

Authors:  Eun Jeong Choi; Woong Shick Ahn
Journal:  Nutr Res Pract       Date:  2008-12-31       Impact factor: 1.926

3.  O-desmethylangolensin inhibits the proliferation of human breast cancer MCF-7 cells by inducing apoptosis and promoting cell cycle arrest.

Authors:  Eun Jeong Choi; Gun-Hee Kim
Journal:  Oncol Lett       Date:  2013-10-01       Impact factor: 2.967

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.